warrenhochfeld

warrenhochfeld

A number of currencies are trending in an inverse price correlation on BTC price drop and accentuated correlation on rise. With BTC dominance (% share of crypto currency market capitalization) decreasing incrementally, this could present an opportunity to capitalize on certain digital assets. This model presents a test-bed for BTC capital outflow and cross...

warrenhochfeld

DASH, BCC, XMR & ETC trending in an inverse price correlation on BTC drop and accentuated correlation on rise. With Bitcoins dominance (% share of crypto currency market capitalization) decreasing incrementally this could present an opportunity to capitalize on certain digital assets. This model presents a test-bed for BTC capital outflow.

warrenhochfeld

Buy at a discount ahead of the 24/12/17 PDUFA decision on A-101 in seborrheic keratosis

warrenhochfeld

Current share price is testing the upward trending lower resistance line. As the lower resistance line crosses the $5 inflection line we could expect major movement ahead of the Q42017/Q12018 FDA catalysts.

warrenhochfeld

NEO has been climbing steadily as capital flows in at a constant rate despite an increase in Chinese regulatory hurdles. When BTC weakens (even if it is just a temporary measure) capital will flow into: 1. Fiat, or 2. USD tether (digital fiat), or 3. Alternative digital currency NEO does not follow Bitcoins price pattern which makes it an excellent choice...

warrenhochfeld

Gas, the fuel that runs the NEO Smart Economy (previously Antshares) has been consolidating for the past 3 months. Chinese regulatory hurdles have caused further price deprecation. This is an undervalued asset with great future potential. Buy.

warrenhochfeld

European launch and approval for additional indications of currently approved drugs will drive further growth. After a long steady decline and a biotech crash, Tesaro is now significantly undervalued.

warrenhochfeld

Pushing down against the lower resistance line. Buy ahead of upcoming PDUFA catalyst

warrenhochfeld

Expected upward trend ahead of 24 January PDUFA label extension for Trulance

warrenhochfeld

ETH has been consolidating in an equilibrium pattern for months. With uncertainty following the recent Bitcoin slump one could hypothesize that capital could flow into lower cap crypto-currencies that have been been growing at a slower rate or declining in an inverse pattern (Ether Classic, Lisk, Dash, Monero, Ark, Neo, Gas).

warrenhochfeld

On Bitcoins recent slump investors are likely to seek lower market cap Bitcoin alternatives with long term growth prospects (Monero, Dash, Ark, Neo, Etc, Lisk, Ether, Gas). Expecting ARK to 5X by the end of 2018.

warrenhochfeld

With an approved product (Omidria) seeing consistent growth and with shares at bargain prices OMER is a high risk high reward biotech opportunity. The pipeline is deep but catalysts will not be seen in the short term. This is a good entry point for a long term position.

warrenhochfeld

After a price crash from a secondary offering (stock dilution) Immune Design Corp Shares present a high risk, high upside biotech investment.

warrenhochfeld

VSTM has a current median price target of $11.00 and Cantor Fitzgerald has reissued its Buy rating at a $17.00 price target. An ascending triangle is currently in formation which could suggest a near term break. The shares now sit on the base of the lower resistance line suggesting a good buy in opportunity for those willing to take on a high risk, high return position.

warrenhochfeld

Possible short term breakout and buy in opportunity for Sage Therapeutics. This could be bull trap which would result in a short term loss of capital, but still a highly undervalued stock at its current price. Buy.

warrenhochfeld

On the expectation that Bitcoin will weaken (temporarily) in the near future investors are likely to seek lesser known lower market cap Bitcoin alternatives with long term growth prospects (Monero, Dash, Ark, Neo, Etc, Lisk). Expecting Golem breakout in the near term.

warrenhochfeld

On the expectation that Bitcoin will weaken (temporarily) in the near future investors are likely to seek lesser known lower market cap Bitcoin alternatives with long term growth prospects (Monero, Dash, Ark, Neo, Etc, Golem). Expecting Lisk to increase at the very least 500% increase by the end of 2018.

warrenhochfeld

Label Expansion Opportunity: seeking approval of Auryxia for the treatment of patients with iron deficiency anemia and non-dialysis dependent chronic kidney disease